Eptiva Therapeutics utilizes a proprietary bioinformatic network biology platform to develop Personalized Analgesics®, linking drug targets and biological pathways to a comprehensive database of pain-related diseases. This approach addresses the high attrition rate in pain drug development by creating precision medicine solutions that enhance treatment efficacy and safety for chronic pain conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Current pain treatments often have limited efficacy, significant side effects, and potential for abuse, while the traditional R&D approach in pain management suffers from a high attrition rate due to reliance on non-translatable preclinical models and a lack of target-to-disease links. Many pain conditions are also neglected in clinical development, leading to a severe lack of innovation in the field.
Solution
Eptiva Therapeutics is developing Personalized Analgesics through a precision medicine approach, utilizing a proprietary bioinformatic network biology platform to link drug targets and biological pathways to a comprehensive database of pain-related diseases. Their approach connects research targets to specific diseases, de-risking R&D and increasing the likelihood of clinical success. The company has developed a 'Pain Diseasome' creating thousands of data nodes via human-focused network biology platforms and a Pain Landscape identifying hundreds of pain-related diseases, including rare and orphan conditions. Eptiva's research platform drives a patient-centered development strategy, creating new pain treatments with precision efficacy and superior safety.
Target Audience
The primary target audience includes chronic pain patients and pharmaceutical companies seeking to develop more effective and safer pain management solutions.
Features
- Proprietary bioinformatic network biology platform linking drug targets and biological pathways to pain-related diseases
- Pain Landscape database identifying hundreds of pain-related diseases, including rare and orphan conditions
- Pain Diseasome creating thousands of data nodes via human-focused network biology platforms
- In-silico modeling to validate new targets for pain research
- Identification of suitable patient groups for clinical development
- Personalized Analgesics research platform for patient-centered development